| ≥.reet | 1 | of | 2 |
|--------|---|----|---|

| FORM PTO 1449 (modified) | | | X-10097 | Serial N 08/484,5 | | | | |
|--------------------------|------|---|-----------------------------|----------------------------------|-------------------------|---------------|----------|-----------------------|
| INFORMAT | | SCLOSURE CITATI | ON | Applicant Brader, Mark L., et | al. | | | |
| | | | Filing Date June 7, 1995 | Group 1645 | | | | |
| <u> </u> | | | U.S. P | ATENT DOCUMENTS: | 200 | | | |
| Examiner | 1 | Document Number | Date | Name | Class | Sub- | Pilin | |
| Initial | | Document Number | Date | AUG 2 1 1 | (- <u> </u> | class | I | g Date f priate |
| mes | AB | 3,907,763 | 9-23-75 | Te > | | | | |
| mag | AC | 4,476,118 | 10-9-84 | Brange, et al. | | | | |
| mex | AD | 5,750, 49-7 | 5-12-98 | Havelund, et al. | | | | |
| | AE | | | | | | | |
| | AF | | | | | · | | |
| | AG | | | | | | | |
| | АН | | | | | | | |
| | AI | | | | | | | |
| | | | | BEST A | /AILABL | E CC | PY | |
| | | | | · | | | | |
| | AJ | | | | | | | |
| | | | FOREIG | N PATENT DOCUMENTS | | | | |
| | | Document Number | Date | Country | Class | Sub- class | Trans | lation |
| | | | | | | | yes | no |
| | BA | | | | | | | |
| | ВВ | | | | | | | |
| | вс | | | | | | | |
| | OTHE | R DOCUMENTS (Inc.) | udina Au | thor, Title, Date, Pert | inent Page | s RfC | ļ | |
| | V | | | , 12020, 2000, 1020 | | , 200 | | |
| mea | СВ | Brange, J., | et al., A | Acta Pharmaceut. Nordic | a, 4:149-1 | 8 (199 | 2) | |
| mer | cc | Brunfeldt, K., et al., Acta. Endocrinol., 61:561-567 (1969) | | | | | | |
| mos | CD | Marble, et a 19-2, p. 382 | l., eds. | , Joslin's Diabetes Mel | litus, 12 th | Ed. (1 | 985) Ta | able |
| EXAMINER | m | Paller | | DATE CONSIDERED | <i>a</i> ¢ | | <u> </u> | |
| *EXAMINER | | | onsidere | d, whether or not citat | | contorm | ance wi | th |
| | Draw | | tion if | not in conformance and | | | | |

of this form with next communication to the applicant.

| 5_1eet | 2 | of | 2 | |
|--------|---|----|---|--|

| FORM PTO | 1449 (mo | odified) | Atty. Docket No. X-10097 | Serial No 08/484,542 | | |
|-----------------------------------|-----------|--|--------------------------------------|---|--|--|
| INFORMATION DISCLOSURE CITATION A | | | Applicant Beckage, Michaeler, et al. | | | |
| | | | Filing Date June 7, 1985 2 1 1000 | Group (4813 /645 | | |
| mas | CE | Markussen, J., et al | ., Prot. Eng., 1:205-21 | (1987) | | |
| MPA | CF | Markussen, J., et al | ., Prot. Eng. 142:1157 16 | 6 (1988) | | |
| most | CG | Montague, W., Diabetes and the Endocrine Pancreas-A Biochemical Approach, 1983, p. 36 | | | | |
| mpa | СН | Foye, W.O., Ed., Principles of Medicinal Chemistry (1974), p. 564 | | | | |
| mpA | CI | Schade, D.S., et al., Intensive Insulin Therapy (1983), pp. 7 and 304 | | | | |
| mos | CJ | Schlichtkrull, J., Insulin Crystals (1958), pp. 21-23, Chapter IV, and pp. 86-88 | | | | |
| mex | СК | Doerge, R.F., Ed., Wilson and Grisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry, 8th Ed. (1982), particularly pp. 774-776 | | | | |
| mos | CL | The United States Pharmacopeia/The National Formulary (1995) pp. 808-813, particularly, p. 809, 811, and 812 | | | | |
| mpt | СМ | Kirk-Othmer, Encyclopedia of Chemical Technology, 3 rd . ed., John Wiley & Sons, New York (1981) Volume 13, pp. 607-614, particularly p. 608, and Table 2 on p. 609 | | | | |
| mps | CN | | / & Sons, Chichester (19 | , Alberti, K. G. M. M., et 992) Volume 1, pp. 836-839, | | |
| | со | | | | | |
| | CP | | | | | |
| | CÕ | | | | | |
| | CR | | | | | |
| | | | BEST AV | AILABLE COPY | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| EXAMINER | mpale | • | DATE CONSIDERED | | | |
| MPEP 609; | Draw line | | not in conformance and | ion is in contormance with not considered. Include copy | | |